Skip to main content
Premium Trial:

Request an Annual Quote

Agilent Completes Acquisition of Dako

NEW YORK (GenomeWeb News) – Agilent Technologies today said that it has completed the acquisition of Dako for $2.2 billion in cash.

Agilent signed the deal to acquire the Danish cancer diagnostics firm last month and said at the time that it would fund the acquisition entirely with its off-shore cash. The acquisition provides Agilent with Dako's immunohistochemistry products and a growing companion diagnostics business.

Didier Hirsch, chief financial officer for Agilent, has said that Dako is expected to generate $373 million in revenues in fiscal 2013 with $68 million operating profit and an operating margin of 18 percent.

As a result of the acquisition, Agilent said that it will now add a fourth business reporting segment, the Diagnostics and Genomics Group. Its three other reporting segments are Life Sciences, Chemical Analysis, and Electronic Measurement.

The new segment consists of Dako, led by Dako CEO Lars Holmkvist, and the Genomics Solutions Division, led by Bob Schueren, VP and GM of Agilent's genomics group. The new segment will report directly to Agilent President and CEO Bill Sullivan.

The Scan

Not as High as Hoped

The Associated Press says initial results from a trial of CureVac's SARS-CoV-2 vaccine suggests low effectiveness in preventing COVID-19.

Finding Freshwater DNA

A new research project plans to use eDNA sampling to analyze freshwater rivers across the world, the Guardian reports.

Rise in Payments

Kaiser Health News investigates the rise of payments made by medical device companies to surgeons that could be in violation of anti-kickback laws.

Nature Papers Present Ginkgo Biloba Genome Assembly, Collection of Polygenic Indexes, More

In Nature this week: a nearly complete Ginkgo biloba genome assembly, polygenic indexes for dozens of phenotypes, and more.